EVAR术中预防性动脉瘤囊栓塞安全且促进囊回缩并减少II型内漏
该回顾性研究纳入44例EVAR患者,预防性行囊内栓塞(PASE),技术成功率100%,无异常栓塞,随访14±11月,65.9%囊回缩,3年免于T2EL为87.1%,无动脉瘤相关死亡。
要点
- 预防性PASE技术成功率100%,无异常栓塞发生。
- 随访中65.9%患者囊回缩,平均囊径减小9 mm。
- 3年免于II型内漏率为87.1%,免于再干预率为83.2%。
核心结论
- 预防性PASE是EVAR中管理瘤囊、预防内漏和促进囊回缩的有效工具,短中期安全有效且持久。
研究设计与样本
- 回顾性分析2015至2019年加州大学圣地亚哥分校和圣地亚哥退伍军人事务医院前瞻性维护数据库,共44例患者。
主要发现
- 技术成功率为100%,未观察到非靶向栓塞。
- 平均随访14±11个月,随访CT患者中100%动脉瘤停止增长,65.9%出现囊回缩。
- 平均瘤囊直径减小9 mm(95%CI 7-12)。
- 3年免于T2EL率为87.1%,随访期间T2EL未导致动脉瘤扩张,无需再干预。
- 免于再干预率为83.2%(针对Ib型内漏和肢体闭塞),无动脉瘤相关死亡。
临床怎么用
- EVAR术中可考虑预防性PASE以促进囊回缩并降低T2EL发生率。
- 术后需影像随访监测内漏和囊径变化。
局限性
- 样本量小(44例),随访时间短(平均14个月),需进一步评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinically significant endoleaks remain costly, time-consuming, morbid and even mortal following endovascular aneurysm repair (EVAR). Perigraft arterial sac embolization (PASE) has been utilized to treat type II endoleaks (T2EL) diagnosed at the time of EVAR or after repair. Our objective was to analyze the safety and efficacy of prophylactic PASE on the incidence of T2EL and aneurysm sac regression in patients undergoing EVAR. METHODS: We performed a retrospective review of prospectively maintained databases from the University of California San Diego and the San Diego Veterans Affairs hospitals between 2015 and 2019. Prophylactic PASE (pPASE) was performed at the time of EVAR with thrombin, contrast and gelfoam liquid embolic aneurysm treatment as previously described. We evaluated technical success, freedom from T2EL, freedom from reintervention, from sac expansion, from type I/III EL, from all-cause mortality (ACM), from aneurysm-related mortality and from non-target embolization (NTE). RESULTS: A total of 44 patients were included in the study. Technical success was 100% and no NTE was observed. The average duration of follow-up was 14 ± 11months. In those treated and followed by CT scan, 100% of patients' aneurysms halted their growth following PASE, while 65.9% demonstrated sac regression. Mean aneurysm sac diameter decreased by 9 mm (95% CI 7-12). At 3 years, freedom from T2EL was 87.1%. Presence of T2EL did not result in aneurysm expansion during the follow-up period and thus did not require reintervention in any of these patients. Freedom from re-intervention was 83.2% for Type Ib EL and limb occlusion and all procedures were determined to be successful at the time of completion. No aneurysm-related deaths occurred during the follow-up. CONCLUSIONS: PASE proves to be an effective tool in sac management for prophylaxis of endoleak and maximizing sac regression in EVAR. It is safe, effective and durable when employed in this manner in the short and medium-term and was associated with low rates of T2ELs and reinterventions and a 100% freedom from sac expansion. Further analysis is required to evaluate the long-term outcomes of this adjunctive procedure in EVAR.
引用
- Mathlouthi A, Guajardo I, Al-Nouri O, et al. Prophylactic Aneurysm Embolization during EVAR Is Safe, Improves Sac Regression and Decreases the Incidence of Type II Endoleak. Ann Vasc Surg. 2021. PMID: 33549781. doi:10.1016/j.avsg.2020.12.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。